These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28501470)

  • 1. Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters.
    Yahata M; Chiba K; Watanabe T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2345-2356. PubMed ID: 28501470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.
    Bourdet DL; Tsuruda PR; Obedencio GP; Smith JA
    J Pharmacol Exp Ther; 2012 Apr; 341(1):137-45. PubMed ID: 22235148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.
    Smith JA; Bourdet DL; Daniels OT; Ding YS; Gallezot JD; Henry S; Kim KH; Kshirsagar S; Martin WJ; Obedencio GP; Stangeland E; Tsuruda PR; Williams W; Carson RE; Patil ST
    Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.
    Matuskey D; Gallezot JD; Nabulsi N; Henry S; Torres K; Dias M; Angarita GA; Huang Y; Shoaf SE; Carson RE; Mehrotra S
    J Psychopharmacol; 2023 Feb; 37(2):164-171. PubMed ID: 36515395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats.
    Liu X; Vilenski O; Kwan J; Apparsundaram S; Weikert R
    Drug Metab Dispos; 2009 Jul; 37(7):1548-56. PubMed ID: 19389861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
    Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):4159-67. PubMed ID: 25980484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
    Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
    Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: the role of free drug concentrations.
    Bundgaard C; Sveigaard C; Brennum LT; Stensbøl TB
    Xenobiotica; 2012 Mar; 42(3):256-65. PubMed ID: 22017605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.
    Takano A; Halldin C; Farde L
    Psychopharmacology (Berl); 2013 Mar; 226(1):147-53. PubMed ID: 23090625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).
    Huang Y; Hwang DR; Bae SA; Sudo Y; Guo N; Zhu Z; Narendran R; Laruelle M
    Nucl Med Biol; 2004 Jul; 31(5):543-56. PubMed ID: 15219271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.
    Frankle WG; Robertson B; Maier G; Paris J; Asmonga D; May M; Himes ML; Mason NS; Mathis CA; Narendran R
    Synapse; 2018 Mar; 72(3):. PubMed ID: 29216407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of FlipIDAM as a SERT-selective SPECT imaging agent.
    Lemoine L; Lieberman BP; Ploessl K; Zheng P; Kung HF
    Nucl Med Biol; 2013 Oct; 40(7):879-86. PubMed ID: 23856117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.
    Plisson C; Stehouwer JS; Voll RJ; Howell L; Votaw JR; Owens MJ; Goodman MM
    J Med Chem; 2007 Sep; 50(19):4553-60. PubMed ID: 17705359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET.
    Baldinger P; Kranz GS; Haeusler D; Savli M; Spies M; Philippe C; Hahn A; Höflich A; Wadsak W; Mitterhauser M; Lanzenberger R; Kasper S
    Neuroimage; 2014 Mar; 88():252-62. PubMed ID: 24121201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters.
    Shiue GG; Choi SR; Fang P; Hou C; Acton PD; Cardi C; Saffer JR; Greenberg JH; Karp JS; Kung HF; Shiue CY
    J Nucl Med; 2003 Dec; 44(12):1890-7. PubMed ID: 14660713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SEP-225289 serotonin and dopamine transporter occupancy: a PET study.
    DeLorenzo C; Lichenstein S; Schaefer K; Dunn J; Marshall R; Organisak L; Kharidia J; Robertson B; Mann JJ; Parsey RV
    J Nucl Med; 2011 Jul; 52(7):1150-5. PubMed ID: 21680689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex.
    Geldof M; Freijer JI; van Beijsterveldt L; Langlois X; Danhof M
    Br J Pharmacol; 2008 Jul; 154(6):1369-78. PubMed ID: 18493251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats.
    Murai N; Fushiki H; Honda S; Murakami Y; Iwashita A; Irie M; Tamura S; Nagakura Y; Aoki T
    Neuroscience; 2015 Mar; 289():262-9. PubMed ID: 25595980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
    Han DD; Gu HH
    BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.